This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group
by Zacks Equity Research
InnovAge Holding, Spirit AeroSystems Holdings, Tandem Diabetes Care and HCI Group have been highlighted in this Screen of The Week article.
4 Toxic Stocks That May Risk Your Peace and Prosperity
by Rimmi Singhi
Stocks like INVV, SPR, TNDM and HCI could prove hazardous for your portfolio. So, it's best to dump these toxic stocks, especially amid the prevailing market mayhem.
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 0.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for InnovAge (INNV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to InnovAge (INNV) stock based on the movements in the options market lately.
Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals
by Zacks Equity Research
Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals are part of zacks screen of the week article.
Detoxify Your Holdings by Steering Clear of These 4 Stocks
by Rimmi Singhi
Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 42.86% and 8.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for InnovAge (INNV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to InnovAge (INNV) stock based on the movements in the options market lately.